[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 174.129.66.66. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 27, 2001

Relationship Between Postmenopausal Hormone Replacement Therapy and Ovarian Cancer

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(24):3089-3090. doi:10.1001/jama.285.24.3089

To the Editor: Dr Rodriguez and colleagues1 suggest that if others confirm their findings, a possible increase in risk of dying from ovarian cancer should be added to the list of possible estrogen-related adverse effects to be discussed with patients considering HRT. They based this recommendation on finding that 31 women died from ovarian cancer among women who in 1982 self-reported using HRT for 10 years or more. This is a relatively small number of events, which weakens the reliability of the conclusions. In addition, other reports on the effect of HRT use on ovarian cancer risk are inconsistent. Of the 5 case-control studies cited by Rodriguez et al that measured ovarian cancer risk among women who used HRT for 5 or more years, 4 found no statistically significant difference.24 One study found a statistically significant increased risk of endometrioid ovarian adenocarcinoma among women who used unopposed estrogen (OR, 2.81; 95% CI, 1.15-6.89).5 For the more common serous carcinomas, the OR of 2.03 was barely statistically significant (95% CI, 1.04-3.97). A recent meta-analysis reported no association between HRT use and ovarian cancer.6

First Page Preview View Large
First page PDF preview
First page PDF preview
×